|
Prolonged Dilatrend
Effect upon the Left Ventricle Systolic |
|
The purpose of our studies was to estimate the influence of the prolonged (1 year) use of Dilatrend, a multifunctional neurohormonal antagonist, upon the left ventricle systolic function in patients with ischemic dilatation cardiomyopathy (DCMP). With that end in view, 89 patients with ischemic DCMP were studied, the mean age 61,5±7,9. The patients were divided into two groups. The cardiac insufficiency treatment of the 1-st group patients (N=49) was done by the traditional scheme (diuretics, ACE inhibitors, peripheral vasodilators). The 2-nd group patients were treated by the traditional therapy plus Dilatrend, at an average, 13,5 mg per day. All the patients underwent transthoracic doppler echocardiography before and after one-year treatment which defined the left ventricle ejection fraction (LV EF), the LV endsystolic ( ESD) and enddiastolic (EDD) dimension; besides, blood pressure was measured, and stenocardic attack rate per week was evaluated. The positive dynamics was noted in both groups against the treatment background: the EF was increased, ESD and EDD as well as systolic and diastolic arterial pressure, and the mean values of stenocardic attack rate were decreased. However, statistically significant difference was achieved in the 2-nd group only. The above enables us to suggest that the introduction of Dilatrend in the cardiac insufficiency traditional treatment significantly raises its effectivene |
|
Reference: 1. Waagstein F., Hjalmarson A., Vamauskas E., Wallentin I. Effect of chronic beta-adrenergic receptor blocade in congestive cardiomyopathy. Br. Heart J.1975; 37:1022-1036. 2. Swedberg K., Hjalmarson A., Vamauskas E., Waagstein F., Wallentin I. Beneficial effects of long-term beta-blocade withdrawal in patients with congestive cardiomyopathy. Br. Heart J.1980; 44:117-133. 3. 3.Bristow M.R. Adrenergic receptor blockade in chronic heart failure. Circulation, 2000; 101:558-569 4. Мареев В.Ю. Изменение стратегии лечения хронической сердечной недостаточности. Время b-адрено блокаторов. Кардиология, 1998;12:4-11 5. 5 Мареев В.Ю. лечение сердечной недостаточности на рубеже веков. Становятся ли положения доказательной медицины доказательствами для практикующих врачей? Кардиология, 2000;12:4-11 6. Ruffalo R.R., Boyle D.A.,Brooks D.P.e.a., Carvedilol: A novel cardiovascular drug with multiple actions. Cardiovasc. Drug Rev..1992; 10:2:127-157. 7. Strein K., Sponer G., Meuller-Beckmann B.,Bartscch W. Pharmacological profile of Carvedilol, a compound with beta-blocking and vasodilating properties. J.Cardiovasc. Pharmacol. 1987;10:Suppl. 11:33-41. 8. Von Moellendorff E., Abshhhagen U., Akpan W., e.a. Clinical pharmacologic investigations with Carvedilol, a new beta-blocker with direct vasodilator activity. Clin. Phaarmacol. Ther. 1986; 39: 677-680 9. 9.Васильев А.П.,Стрельцова Н.Н., Горбунова Т.Ю. Значение антиоксидантных свойств карведилола при воздействии на процессы ремоделирования сердца у больных ишемической болезни сердца с начальными проявлениями сердечной недостаточности. Кардиология, 2003; том 43, 2: 69-70 10. 10 Packer M., Bristow M.R., Cohn J.N. e.a. The effect of Carvedilol on morbidity and mortality in patients with chronic heart failure. N.Engl.J. Med. 1996; 334: 1349-1355 11. Bristow M.R., Packer M., e.a. Multicenter oral Carvedilol heart failure assessment (MOCHA): A six month dose-response evaluation in class II-IV patients. Circulation, 1995; 92: 1:1-142
|